In current buying and selling, shares of Kymera Therapeutics Inc (Image: KYMR) have crossed above the common analyst 12-month goal worth of $69.20, altering arms for $70.15/share. When a inventory reaches the goal an analyst has set, the analyst logically has two methods to react: downgrade www.nasdaq.com
In current buying and selling, shares of Kymera Therapeutics Inc (Image: KYMR) have crossed above the common analyst 12-month goal worth of $69.20, altering arms for $70.15/share. When a inventory reaches the goal an analyst has set, the analyst logically has two methods to react: downgrade
www.nasdaq.com